Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine.

Mudiope PK, Kim S, Wabwire D, Nyende L, Bagenda D, Mubiru M, Mulira R, Elbireer S, Namukwaya Z, Fowler MG, Musoke P.

Trop Med Int Health. 2013 Mar;18(3):344-51. doi: 10.1111/tmi.12054. Epub 2013 Jan 4.

2.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
3.

Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine.

Chi BH, Sinkala M, Stringer EM, Cantrell RA, Mtonga V, Bulterys M, Zulu I, Kankasa C, Wilfert C, Weidle PJ, Vermund SH, Stringer JS.

AIDS. 2007 May 11;21(8):957-64.

4.

Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.

Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, Rouet F, Becquet R, Leroy V, El-Sadr WM, Abrams EJ, Dabis F.

PLoS Med. 2007 Aug;4(8):e257.

5.

Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.

Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG.

J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):350-64.

PMID:
11468423
6.

Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months.

Chintu N, Giganti MJ, Putta NB, Sinkala M, Sadoki E, Stringer EM, Stringer JS, Chi BH.

Trop Med Int Health. 2010 Jul;15(7):842-7. doi: 10.1111/j.1365-3156.2010.02540.x. Epub 2010 May 7.

7.

The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, January 2007 to May 2009.

Namukwaya Z, Mudiope P, Kekitiinwa A, Musoke P, Matovu J, Kayma S, Salmond W, Bitarakwate E, Mubiru M, Maganda A, Galla M, Byamugisha J, Fowler MG.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):69-75. doi: 10.1097/QAI.0b013e3181fdb4a8.

PMID:
21099692
8.

Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda.

McConnell M, Bakaki P, Eure C, Mubiru M, Bagenda D, Downing R, Matovu F, Thigpen MC, Greenberg AE, Fowler MG.

J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):291-6.

PMID:
18167645
9.

Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count.

Omer SB; Six Week Extended Dose Nevirapine (SWEN) Study Team.

AIDS. 2011 Mar 27;25(6):767-76. doi: 10.1097/QAD.0b013e328344c12a. Erratum in: AIDS. 2012 Nov 28;26(18):2427-8.

PMID:
21330912
10.

Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.

Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, Leroy V, Blanche S, Dabis F, Abrams EJ.

AIDS. 2008 Sep 12;22(14):1815-20. doi: 10.1097/QAD.0b013e32830b8ab9.

PMID:
18753864
11.

Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.

Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, Thigpen MC, Li Q, Kumwenda NI, Mofenson L.

J Infect Dis. 2009 Nov 15;200(10):1490-7. doi: 10.1086/644598.

PMID:
19832114
12.

Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia.

Kuhn L, Semrau K, Ramachandran S, Sinkala M, Scott N, Kasonde P, Mwiya M, Kankasa C, Decker D, Thea DM, Aldrovandi GM.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):132-6. doi: 10.1097/QAI.0b013e3181ab6d5e.

13.

Response to antiretroviral therapy after a single, peripartum dose of nevirapine.

Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van Widenfelt E, Mazhani L, Novitsky V, Lagakos S, Essex M.

N Engl J Med. 2007 Jan 11;356(2):135-47.

14.

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.

Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A.

HIV Med. 2004 Mar;5(2):105-9.

16.

Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.

van Leth F, Wit FW, Reiss P, Schattenkerk JK, van der Ende ME, Schneider MM, Mulder JW, Frissen PH, de Wolf F, Lange JM.

HIV Med. 2004 Mar;5(2):74-81.

17.

Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012.

Eshleman SH, Guay LA, Mwatha A, Brown E, Musoke P, Mmiro F, Jackson JB.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):593-7.

PMID:
16044013
18.

Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.

Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Muñoz L, Gómez Sirvent JL, Vidal F, López-Aldeguer J, Blanco JR, Leal M, Rodríguez-Arenas MA, Perez Hoyos S; CoRIS-MD.

PLoS One. 2006 Dec 20;1:e89.

19.

Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.

Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangclaviraj S, Limpongsanurak S, Jadwattanakul T, Eiamapichart P, Luesomboon W, Apisarnthanarak A, Kamudhamas A, Tangsathapornpong A, Vitavasiri C, Singhakowinta N, Attakornwattana V, Kriengsinyot R, Methajittiphun P, Chunloy K, Preetiyathorn W, Aumchantr T, Toro P, Abrams EJ, El-Sadr W, Phanuphak P.

HIV Med. 2007 Sep;8(6):357-66.

20.

Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.

Hermans SM, Manabe YC, Kiragga AN, Hoepelman AI, Lange JM, van Leth F.

Antivir Ther. 2013;18(4):615-22. doi: 10.3851/IMP2525. Epub 2013 Feb 19.

PMID:
23423604

Supplemental Content

Support Center